Business Wire - Sepracor Announces Presentation of LUNESTA™ Posters at Associated Professional Sleep Societies Annual Meeting
MARLBOROUGH, Mass. — Sepracor Inc. (Nasdaq: SEPR) today announced that data for LUNESTA(TM) brand eszopiclone for the treatment of insomnia were presented at the SLEEP 2006 20th Anniversary Meeting of the Associated Professional Sleep Societies in Salt Lake City. The data included four poster presentations of results from LUNESTA Phase IIIB/IV studies.
Two Double-Blind, Placebo-Controlled, 6-Month Trials of Eszopiclone for Insomnia: Pooled Analysis by Race/Ethnicity
Related Results
Hallucinations associated with initiation of guanfacine.(Letters to the Edito…
Labopharm Initiates Phase III Clinical Study for Once-Daily Formulation of Tr…
Impotence and hypnosis
Trazodone
URL Mutual Unveils Unit-of-Use Initiative.(United Research Laboratories and M…
Results of two similar six-month, double-blind, placebo-controlled studies of LUNESTA 3 mg for the treatment of insomnia were pooled and analyzed by stratifying by race/ethnicity for 1,581 patients. The analysis examined patient response to LUNESTA across various sleep parameters including sleep latency (time to sleep onset), wake time after sleep onset (WASO, a measure of sleep maintenance), total sleep time (TST), daytime alertness, ability to function and sense of physical well-being. In this analysis, Caucasians (n=1,195) and African-Americans (n=236) who were administered LUNESTA achieved statistically significant (p
